Cellular therapies are moving beyond blood cancers into non-oncology indications like stiff-person syndrome and myasthenia gravis, creating major operational challenges for healthcare systems. According to Zahra Mahmoudjafari, clinical pharmacy manager in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Health System, this shift will require institutions to adapt to a vastly different and larger patient volume within the next two years.
Operational Challenges of Non-Oncology CAR T-Cell Therapy
Expanding CAR T-cell therapy outside of hematologic malignancies brings distinct logistical hurdles for hospitals and clinics. Mahmoudjafari, speaking at the National ICE-T Conference in Orlando, noted that the patient population for conditions such as myasthenia gravis is categorically larger than the typical blood cancer cohort. Health systems must figure out how to scale their infrastructure to handle this influx without disrupting existing oncology care.
Up to this point, bispecific antibodies and cellular therapies have remained largely confined to hematology departments.
Anticipated Approvals for Stiff-Person Syndrome and Myasthenia Gravis
Regulatory milestones for non-oncology cellular therapy are drawing closer. Mahmoudjafari anticipates an approval for stiff-person syndrome in the near term, with myasthenia gravis indications likely following soon after. While an approval timeline spanning the next 12 months might prove ambitious, clinical teams should expect active treatment protocols within a 24-month window, according to program leadership.
Did you know?
Frequently Asked Questions
What are the main non-oncology indications being targeted for CAR T-cell therapy?
Program leadership at the National ICE-T Conference highlighted stiff-person syndrome and myasthenia gravis as the primary non-oncology indications approaching potential regulatory approval.
Why is expanding cell therapy to autoimmune diseases an operational challenge?
According to Zahra Mahmoudjafari, the patient volume for conditions like myasthenia gravis is significantly larger than current hematology volumes, requiring health systems to rapidly adapt their infrastructure and staffing.
When are these non-oncology treatments expected to reach clinical practice?
Experts anticipate clinical conversations and treatment implementation for expanded cell therapy-eligible populations within the next two years.
Want to stay ahead of the latest shifts in cellular therapy and oncology? Subscribe to our newsletter for expert updates, or explore our clinical archive for more coverage from the National ICE-T Conference.
Worth a look